Source 1primary paper2025MED
Toolkit/dual-targeting CARs
dual-targeting CARs
Also known as: bispecific CAR-Ts
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
The review delves into ongoing efforts in preclinical models, translational advancements, and emerging approaches such as dual-targeting CARs, armored CARs, and alternative co-stimulatory domains.
Usefulness & Problems
Why this is useful
Dual-targeting CARs are presented as CAR-T designs that recognize more than one antigen-related input to address heterogeneous solid tumors. The abstract also notes promising clinical trials of bispecific CAR-Ts.; countering antigen heterogeneity in solid tumors; Dual-targeting CARs are presented as an emerging CAR design approach within next-generation CAR T-cell engineering.; next-generation CAR design; enhancing CAR T-cell efficacy
Source:
Dual-targeting CARs are presented as CAR-T designs that recognize more than one antigen-related input to address heterogeneous solid tumors. The abstract also notes promising clinical trials of bispecific CAR-Ts.
Source:
countering antigen heterogeneity in solid tumors
Source:
Dual-targeting CARs are presented as an emerging CAR design approach within next-generation CAR T-cell engineering.
Source:
next-generation CAR design
Source:
enhancing CAR T-cell efficacy
Problem solved
This strategy is explicitly presented as a way to counter antigen heterogeneity in solid tumors.; antigen heterogeneity; The abstract links emerging CAR innovations to overcoming antigen heterogeneity and tumor antigen escape.; addressing antigen heterogeneity; addressing tumor antigen escape
Source:
This strategy is explicitly presented as a way to counter antigen heterogeneity in solid tumors.
Source:
antigen heterogeneity
Source:
The abstract links emerging CAR innovations to overcoming antigen heterogeneity and tumor antigen escape.
Source:
addressing antigen heterogeneity
Source:
addressing tumor antigen escape
Problem links
addressing antigen heterogeneity
LiteratureThe abstract links emerging CAR innovations to overcoming antigen heterogeneity and tumor antigen escape.
Source:
The abstract links emerging CAR innovations to overcoming antigen heterogeneity and tumor antigen escape.
addressing tumor antigen escape
LiteratureThe abstract links emerging CAR innovations to overcoming antigen heterogeneity and tumor antigen escape.
Source:
The abstract links emerging CAR innovations to overcoming antigen heterogeneity and tumor antigen escape.
antigen heterogeneity
LiteratureThis strategy is explicitly presented as a way to counter antigen heterogeneity in solid tumors.
Source:
This strategy is explicitly presented as a way to counter antigen heterogeneity in solid tumors.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
multi-antigen targetingsynthetic antigen recognition by genetically reprogrammed t cellsTranslation ControlTechniques
No technique tags yet.
Target processes
manufacturingtranslationImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: regulatorswitch architecture: single chain
Implementation requires engineered bispecific or dual-targeting CAR-T products. The abstract does not specify the exact circuit architecture.; requires more complex CAR-T engineering and manufacturing
The abstract states that manufacturing complexity and off-target effects remain challenges, so the approach does not eliminate those issues.; manufacturing complexity; off-target effects; The abstract does not provide construct-level details or evidence that dual-targeting CARs resolve all toxicity or resistance issues.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Source 2primary paper2025MED
Ranked Claims
Hypoxia-inducible CARs restrict CAR-T activity to tumor sites.
SynNotch CARs restrict CAR-T activity to tumor sites.
Current CAR T-cell therapy faces challenges including antigen heterogeneity, toxicity, resistance, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and tumor antigen escape.
Clinical trials of bispecific CAR-Ts show promise.
Nanobody-based CAR-T cells offer improved stability, tumor penetration, and reduced immunogenicity compared with single-chain variable fragment constructs.
CAR T-cell therapy deployment is limited by ethical, economic, and logistical challenges including access disparities, manufacturing constraints, and the need for value-based pricing models.
Manufacturing complexity and off-target effects remain challenges for engineered CAR-T approaches in solid tumors.
CAR T-cell therapy works by genetically reprogramming autologous T cells to express synthetic receptors targeting tumor-specific antigens, enabling robust antitumor responses.
Armored CARs secreting IL-12 or checkpoint inhibitors remodel the tumor microenvironment.
Emerging CAR engineering approaches discussed for improving CAR T-cell efficacy include dual-targeting CARs, armored CARs, and alternative co-stimulatory domains.
Cytokine-armed TRUCKs enhance CAR-T persistence and function.
Dual-targeting CARs counter antigen heterogeneity in solid tumors.
CAR T-cell therapy has emerged as a major cancer immunotherapy modality with notable clinical benefit, especially in hematologic malignancies.
Chemokine receptor engineering enhances CAR-T infiltration.
Approval Evidence
2 sources4 linked approval claimsfirst-pass slug dual-targeting-cars
The review delves into ongoing efforts in preclinical models, translational advancements, and emerging approaches such as dual-targeting CARs, armored CARs, and alternative co-stimulatory domains.
Source:
Dual-targeting CARs counter antigen heterogeneity... Clinical trials of bispecific CAR-Ts show promise
Source:
clinical progresssupports
Clinical trials of bispecific CAR-Ts show promise.
Source:
limitationsupports
Manufacturing complexity and off-target effects remain challenges for engineered CAR-T approaches in solid tumors.
Source:
next generation strategysupports
Emerging CAR engineering approaches discussed for improving CAR T-cell efficacy include dual-targeting CARs, armored CARs, and alternative co-stimulatory domains.
Source:
problem mitigationsupports
Dual-targeting CARs counter antigen heterogeneity in solid tumors.
Source:
Comparisons
Source-stated alternatives
Alternatives mentioned in the abstract include hypoxia-inducible CARs, SynNotch CARs, chemokine receptor engineering, armored CARs, nanobody-based CAR-T cells, and safety-control systems.; Nearby alternatives named in the abstract include armored CARs and alternative co-stimulatory domains.
Source:
Alternatives mentioned in the abstract include hypoxia-inducible CARs, SynNotch CARs, chemokine receptor engineering, armored CARs, nanobody-based CAR-T cells, and safety-control systems.
Source:
Nearby alternatives named in the abstract include armored CARs and alternative co-stimulatory domains.
Source-backed strengths
described as countering antigen heterogeneity; clinical trials are described as showing promise; presented as an emerging approach to enhance efficacy and overcome challenges
Source:
described as countering antigen heterogeneity
Source:
clinical trials are described as showing promise
Source:
presented as an emerging approach to enhance efficacy and overcome challenges
Compared with armored CARs
Alternatives mentioned in the abstract include hypoxia-inducible CARs, SynNotch CARs, chemokine receptor engineering, armored CARs, nanobody-based CAR-T cells, and safety-control systems.; Nearby alternatives named in the abstract include armored CARs and alternative co-stimulatory domains.
Shared frame: source-stated alternative in extracted literature
Strengths here: described as countering antigen heterogeneity; clinical trials are described as showing promise; presented as an emerging approach to enhance efficacy and overcome challenges.
Relative tradeoffs: manufacturing complexity; off-target effects.
Source:
Alternatives mentioned in the abstract include hypoxia-inducible CARs, SynNotch CARs, chemokine receptor engineering, armored CARs, nanobody-based CAR-T cells, and safety-control systems.
Source:
Nearby alternatives named in the abstract include armored CARs and alternative co-stimulatory domains.
Compared with CAR-T
Alternatives mentioned in the abstract include hypoxia-inducible CARs, SynNotch CARs, chemokine receptor engineering, armored CARs, nanobody-based CAR-T cells, and safety-control systems.
Shared frame: source-stated alternative in extracted literature
Strengths here: described as countering antigen heterogeneity; clinical trials are described as showing promise; presented as an emerging approach to enhance efficacy and overcome challenges.
Relative tradeoffs: manufacturing complexity; off-target effects.
Source:
Alternatives mentioned in the abstract include hypoxia-inducible CARs, SynNotch CARs, chemokine receptor engineering, armored CARs, nanobody-based CAR-T cells, and safety-control systems.
Compared with CAR-T cells
Alternatives mentioned in the abstract include hypoxia-inducible CARs, SynNotch CARs, chemokine receptor engineering, armored CARs, nanobody-based CAR-T cells, and safety-control systems.
Shared frame: source-stated alternative in extracted literature
Strengths here: described as countering antigen heterogeneity; clinical trials are described as showing promise; presented as an emerging approach to enhance efficacy and overcome challenges.
Relative tradeoffs: manufacturing complexity; off-target effects.
Source:
Alternatives mentioned in the abstract include hypoxia-inducible CARs, SynNotch CARs, chemokine receptor engineering, armored CARs, nanobody-based CAR-T cells, and safety-control systems.
Compared with CAR-T cell therapy
Alternatives mentioned in the abstract include hypoxia-inducible CARs, SynNotch CARs, chemokine receptor engineering, armored CARs, nanobody-based CAR-T cells, and safety-control systems.
Shared frame: source-stated alternative in extracted literature
Strengths here: described as countering antigen heterogeneity; clinical trials are described as showing promise; presented as an emerging approach to enhance efficacy and overcome challenges.
Relative tradeoffs: manufacturing complexity; off-target effects.
Source:
Alternatives mentioned in the abstract include hypoxia-inducible CARs, SynNotch CARs, chemokine receptor engineering, armored CARs, nanobody-based CAR-T cells, and safety-control systems.
Compared with CAR-T therapy
Alternatives mentioned in the abstract include hypoxia-inducible CARs, SynNotch CARs, chemokine receptor engineering, armored CARs, nanobody-based CAR-T cells, and safety-control systems.
Shared frame: source-stated alternative in extracted literature
Strengths here: described as countering antigen heterogeneity; clinical trials are described as showing promise; presented as an emerging approach to enhance efficacy and overcome challenges.
Relative tradeoffs: manufacturing complexity; off-target effects.
Source:
Alternatives mentioned in the abstract include hypoxia-inducible CARs, SynNotch CARs, chemokine receptor engineering, armored CARs, nanobody-based CAR-T cells, and safety-control systems.
Compared with Chemokine receptor engineering
Alternatives mentioned in the abstract include hypoxia-inducible CARs, SynNotch CARs, chemokine receptor engineering, armored CARs, nanobody-based CAR-T cells, and safety-control systems.
Shared frame: source-stated alternative in extracted literature
Strengths here: described as countering antigen heterogeneity; clinical trials are described as showing promise; presented as an emerging approach to enhance efficacy and overcome challenges.
Relative tradeoffs: manufacturing complexity; off-target effects.
Source:
Alternatives mentioned in the abstract include hypoxia-inducible CARs, SynNotch CARs, chemokine receptor engineering, armored CARs, nanobody-based CAR-T cells, and safety-control systems.
Compared with Chimeric Antigen Receptor (CAR) T-cell therapy
Alternatives mentioned in the abstract include hypoxia-inducible CARs, SynNotch CARs, chemokine receptor engineering, armored CARs, nanobody-based CAR-T cells, and safety-control systems.
Shared frame: source-stated alternative in extracted literature
Strengths here: described as countering antigen heterogeneity; clinical trials are described as showing promise; presented as an emerging approach to enhance efficacy and overcome challenges.
Relative tradeoffs: manufacturing complexity; off-target effects.
Source:
Alternatives mentioned in the abstract include hypoxia-inducible CARs, SynNotch CARs, chemokine receptor engineering, armored CARs, nanobody-based CAR-T cells, and safety-control systems.
Compared with chimeric antigen receptor T cells
Alternatives mentioned in the abstract include hypoxia-inducible CARs, SynNotch CARs, chemokine receptor engineering, armored CARs, nanobody-based CAR-T cells, and safety-control systems.
Shared frame: source-stated alternative in extracted literature
Strengths here: described as countering antigen heterogeneity; clinical trials are described as showing promise; presented as an emerging approach to enhance efficacy and overcome challenges.
Relative tradeoffs: manufacturing complexity; off-target effects.
Source:
Alternatives mentioned in the abstract include hypoxia-inducible CARs, SynNotch CARs, chemokine receptor engineering, armored CARs, nanobody-based CAR-T cells, and safety-control systems.
Compared with Chimeric antigen receptor T-cell therapy
Alternatives mentioned in the abstract include hypoxia-inducible CARs, SynNotch CARs, chemokine receptor engineering, armored CARs, nanobody-based CAR-T cells, and safety-control systems.
Shared frame: source-stated alternative in extracted literature
Strengths here: described as countering antigen heterogeneity; clinical trials are described as showing promise; presented as an emerging approach to enhance efficacy and overcome challenges.
Relative tradeoffs: manufacturing complexity; off-target effects.
Source:
Alternatives mentioned in the abstract include hypoxia-inducible CARs, SynNotch CARs, chemokine receptor engineering, armored CARs, nanobody-based CAR-T cells, and safety-control systems.
Compared with coherent anti-Stokes Raman scattering
Alternatives mentioned in the abstract include hypoxia-inducible CARs, SynNotch CARs, chemokine receptor engineering, armored CARs, nanobody-based CAR-T cells, and safety-control systems.; Nearby alternatives named in the abstract include armored CARs and alternative co-stimulatory domains.
Shared frame: source-stated alternative in extracted literature
Strengths here: described as countering antigen heterogeneity; clinical trials are described as showing promise; presented as an emerging approach to enhance efficacy and overcome challenges.
Relative tradeoffs: manufacturing complexity; off-target effects.
Source:
Alternatives mentioned in the abstract include hypoxia-inducible CARs, SynNotch CARs, chemokine receptor engineering, armored CARs, nanobody-based CAR-T cells, and safety-control systems.
Source:
Nearby alternatives named in the abstract include armored CARs and alternative co-stimulatory domains.
Compared with Hypoxia-inducible CARs
Alternatives mentioned in the abstract include hypoxia-inducible CARs, SynNotch CARs, chemokine receptor engineering, armored CARs, nanobody-based CAR-T cells, and safety-control systems.
Shared frame: source-stated alternative in extracted literature
Strengths here: described as countering antigen heterogeneity; clinical trials are described as showing promise; presented as an emerging approach to enhance efficacy and overcome challenges.
Relative tradeoffs: manufacturing complexity; off-target effects.
Source:
Alternatives mentioned in the abstract include hypoxia-inducible CARs, SynNotch CARs, chemokine receptor engineering, armored CARs, nanobody-based CAR-T cells, and safety-control systems.
Compared with Nanobody-based CAR-T cells
Alternatives mentioned in the abstract include hypoxia-inducible CARs, SynNotch CARs, chemokine receptor engineering, armored CARs, nanobody-based CAR-T cells, and safety-control systems.
Shared frame: source-stated alternative in extracted literature
Strengths here: described as countering antigen heterogeneity; clinical trials are described as showing promise; presented as an emerging approach to enhance efficacy and overcome challenges.
Relative tradeoffs: manufacturing complexity; off-target effects.
Source:
Alternatives mentioned in the abstract include hypoxia-inducible CARs, SynNotch CARs, chemokine receptor engineering, armored CARs, nanobody-based CAR-T cells, and safety-control systems.
Ranked Citations
- 1.
- 2.